Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities:
Net loss	$ (63,866)	$ (19,498)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash royalty revenue related to sale of future royalties	(6,663)	(6,535)
Non-cash interest expense on liability related to sale of future royalties	4,552	5,045
Stock-based compensation	8,184	6,363
Depreciation and amortization	4,033	3,715
Other non-cash transactions	(731)	(617)
Changes in operating assets and liabilities:
Accounts receivable, net	14,113	(19,730)
Inventory	(1,907)	96
Other assets	2,134	4,294
Accounts payable	4,117	(34)
Accrued compensation	(6,817)	4,046
Accrued clinical trial expenses	(515)	2,376
Other accrued expenses	1,798	2,176
Interest payable	(108)	(54)
Deferred revenue	9,619	(7,027)
Other liabilities	(2,509)	1,736
Net cash used in operating activities	(34,566)	(23,648)
Cash flows from investing activities:
Purchases of investments	(75,857)	(31,452)
Maturities of investments	58,053	69,377
Sales of investments	8,823	0
Purchases of property, plant and equipment	(4,089)	(1,679)
Net cash (used in) provided by investing activities	(13,070)	36,246
Cash flows from financing activities:
Payment of capital lease obligations	(613)	(1,723)
Proceeds from shares issued under equity compensation plans	11,792	6,096
Net cash provided by financing activities	11,179	4,373
Effect of exchange rates on cash and cash equivalents	297	8
Net (decrease) increase in cash and cash equivalents	(36,160)	16,979
Cash and cash equivalents at beginning of period	59,640	55,570
Cash and cash equivalents at end of period	23,480	72,549
Supplemental disclosure of cash flow information:
Cash paid for interest	$ 5,067	$ 5,244